Use of 5-HT4 modulators for the manufacture of a medicament for the treatment of the bladder diseases

Abstract

A compound which acts as an antagonist at 5-HT 4 receptors is of potential use in the treatment of conditions associated with bladder hypersensitivity, such as urinary incontinence, which is often associated with irritable bowel syndrome (IBS) and a compound which acts as an agonist at 5-HT 4 receptors is of potential use in the treatment of conditions associated with a poorly functioning bladder, such as urinary bladder hypoactivity following prostectomy.

1 . A method for the treatment and/or prophylaxis of conditions associated with bladder hypersensitivity and conditions associated with a poorly functioning bladder in mammals, including humans, which method comprises administering to the mammal in need of such treatment and/or prophylaxis, an effective and/or prophylactic amount of a 5-HT 4  modulator.  
     
     
         2 . The use of a 5-HT 4  modulator in the manufacture of a medicament for use in the treatment and/or prophylaxis of conditions associated with a poorly functioning bladder and bladder hypersensitivity.  
     
     
         3 . A pharmaceutical composition for use in the treatment and/or prophylaxis of conditions associated with a poorly functioning bladder and bladder hypersensitivity, which comprises a 5-HT 4  modulator, and a pharmaceutically acceptable carrier.  
     
     
         4 . A method, use or composition according to  claim 1 ,  2  or  3  wherein the 5-HT 4  modulator is a 5-HT 4  receptor antagonist.  
     
     
         5 . A method, use or composition according to  claim 4  for the treatment of urinary incontinence.  
     
     
         6 . A method, use or composition according to  claim 5  for the treatment of urinary incontinence associated with irritable bowel syndrome.  
     
     
         7 . A method, use or composition according to  claim 4 ,  5  or  6  wherein 5-HT 4  receptor antagonist is R 50 595, SDZ 205-557, DAU 6285, RS 23597-190 or a compound described in relation to EP-A-501322 (Glaxo Group Limited).  
     
     
         8 . A method, use or composition according to  claim 1 ,  2  or  3  wherein the 5-HT 4  modulator is a 5-HT 4  receptor agonist.  
     
     
         9 . A method, use or composition according to  claim 8  for the treatment of urinary bladder hypoactivity following prostectomy.  
     
     
         10 . A method, use or composition according to  claim 8  or  9  wherein 5-HT 4  receptor agonist is cisapride, renzapride or zacopride.